2024 • Volume • • Electronic publication date: 13/05/2024

Meningococcal Surveillance Australia Reporting period 1 October to 31 December 2023

Monica M Lahra and Tiffany R Hogan for the National Neisseria Network

The reference laboratories of the National Neisseria Network, Australia report data on invasive meningococcal disease (IMD) cases confirmed by culture and or molecular techniques for the Australian Meningococcal Surveillance Programme (AMSP). Culture-positive cases and molecular-based diagnoses are defined as IMD by the Communicable Diseases Network Australia National Guidelines for Public Health Units.1 Data contained in the quarterly reports are restricted to a description of the number of cases by jurisdiction and serogroup, when known. Some minor corrections to data in Table 1 may be made in subsequent reports if additional data are received.

In Australia, IMD notifications in the fourth quarter of 2023 were the same as in the corresponding period in 2022 (n = 32); however, the year-to-date notifications increased from 118 in 2022 to 134 in 2023 (Table 1). There has been a gradual resurgence of IMD in Australia since 2021 (n = 67).2 This follows public health restrictions during the pandemic, and is coincident with expanded coverage of national immunisation programmes; however, IMD notifications remain lower than reported in 2019 (n = 202).3,4 In 2023, MenB remains the main cause of IMD in Australia, accounting for 82.8% (106/128) of notifications where a serogroup was detected.

Table 1: Number of laboratory confirmations of invasive meningococcal disease, Australia, 1 October to 31 December 2023, by serogroup and state or territory

|  |  |
| --- | --- |
| Jurisdiction | Serogroup |
| Year | **A** | **B** | **C** | **W** | **Y** | **NDa** | **All** |
| **Q4** | **ytdb** | **Q4** | **ytd** | **Q4** | **ytd** | **Q4** | **ytd** | **Q4** | **ytd** | **Q4** | **ytd** | **Q4** | **ytd** |
| Australian Capital Territory | 2023 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | **0** | **2** |
| 2022 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | **1** | **2** |
| New South Wales | 2023 | 0 | 0 | 4 | 23 | 0 | 0 | 0 | 2 | 0 | 5 | 0 | 0 | **4** | **30** |
| 2022 | 0 | 0 | 10 | 31 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | **11** | **33** |
| Northern Territory | 2023 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | **2** | **3** |
| 2022 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | **0** | **2** |
| Queensland | 2023 | 0 | 0 | 7 | 35 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 4 | **10** | **41** |
| 2022 | 0 | 0 | 8 | 23 | 0 | 0 | 0 | 2 | 0 | 5 | 0 | 1 | **8** | **31** |
| South Australia | 2023 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 3 | 1 | 1 | 0 | 0 | **1** | **20** |
| 2022 | 0 | 0 | 1 | 12 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | **2** | **14** |
| Tasmania | 2023 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | **1** | **5** |
| 2022 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | **1** | **2** |
| Victoria | 2023 | 0 | 0 | 8 | 20 | 0 | 0 | 1 | 3 | 1 | 2 | 0 | 1 | **10** | **26** |
| 2022 | 0 | 0 | 4 | 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | **4** | **15** |
| Western Australia | 2023 | 0 | 0 | 4 | 6 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | **4** | **7** |
| 2022 | 0 | 0 | 5 | 14 | 0 | 0 | 0 | 3 | 0 | 2 | 0 | 0 | **5** | **19** |
| **Australia** | **2023** | 0 | 0 | 25 | 106 | 0 | 0 | 2 | 11 | 3 | 11 | 2 | 6 | **32** | **134** |
| 2022 | 0 | 0 | 30 | 99 | 0 | 0 | 0 | 5 | 2 | 10 | 0 | 4 | 32 | 118 |

a ND: not determined.

b ytd: year to date, data from 1 January to 31 December 2023.

# Author details

Monica M Lahra1,2

Tiffany R Hogan1

1. The World Health Organization Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, The Prince of Wales Hospital, Randwick, NSW 2031, Australia
2. School of Medical Sciences, Faculty of Medicine, the University of New South Wales, Kensington, NSW 2052, Australia

Corresponding author

Professor Monica M Lahra

The World Health Organization Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, NSW Health Pathology Microbiology, The Prince of Wales Hospital, Randwick, NSW 2031, Australia

Telephone: +61 2 9382 3678

Facsimile: +61 2 9382 3720

Email: monica.lahra@health.nsw.gov.au

# References

1. Australian Government Department of Health and Aged Care, Communicable Diseases Network Australia (CDNA). Invasive Meningococcal Disease: CDNA National Guidelines for Public Health Units. Canberra: Australian Government Department of Health and Aged Care; 4 July 2017. Available from: https://www.health.gov.au/sites/default/files/documents/2020/02/invasive-meningococcal-disease-cdna-national-guidelines-for-public-health-units.pdf.
2. Lahra MM, George CRR, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2021 for the National Neisseria Network. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.46.
3. George CRR, Booy R, Nissen MD, Lahra MM. The decline of invasive meningococcal disease and influenza in the time of COVID‐19: the silver linings of the pandemic playbook Med J Aust. 2022;216(10):504–7. https://doi.org/10.5694/mja2.51463.
4. Lahra MM, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2019 for the National Neisseria Network. Commun Dis Intell (2018). 2020;44. doi: https://doi.org/10.33321/cdi.2020.44.62.

Communicable Diseases Intelligence

Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Health Protection Policy & Surveillance Division, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.

© 2024 Commonwealth of Australia as represented by the Department of Health and Aged Care

ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (CC BY-NC-ND) available from https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**

The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at www.pmc.gov.au/resources/commonwealth-coat-arms-information-and-guidelines);
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**

Opinions expressed in *Communicable Diseases Intelligence* are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**

Enquiries regarding any other use of this publication should be addressed to the CDI Editor at: cdi.editor@health.gov.au

**Communicable Diseases Network Australia**

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia. www.health.gov.au/cdna

**Editor**: Christina Bareja • **Deputy Editor**: Simon Petrie • **Design and Production**: Lisa Thompson

**Editorial Advisory Board**: David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk, Meru Sheel and Stephanie Williams

**Contacts**

CDI is produced by:

Health Protection Policy & Surveillance Division, Australian Government Department of Health and Aged Care,
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

Website: www.health.gov.au/cdi

Email: cdi.editor@health.gov.au

**Submit an Article**

You are invited to submit your next communicable disease related article to the *Communicable Diseases Intelligence* (CDI) for consideration. More information regarding CDI can be found at: www.health.gov.au/cdi.

Further enquiries should be directed to: cdi.editor@health.gov.au.